Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Hepatitis D Market Size Outlook: How Fast Will Revenue Grow Through 2030?

The global hepatitis D market experienced consistent expansion historically and is projected to continue this upward trend. Anticipated to increase from $0.76 billion in 2025 to $0.79 billion in 2026, this growth represents a compound annual growth rate (CAGR) of 4.4%. Key factors driving the market’s historical growth include enhanced hepatitis B screening rates, greater acknowledgment of the severity associated with HDV infection, advancements in diagnostic technologies, a rise in patient referrals to specialized care facilities, and the introduction of specific treatment options.

The market for Hepatitis D is projected for consistent expansion over the approaching years, reaching an estimated $0.93 billion by 2030, driven by a compound annual growth rate of 4.1%. This anticipated growth throughout the forecast period is fueled by several key factors, including intensified research endeavors focused on innovative treatments for HDV, a heightened emphasis on employing combination antiviral therapies, the broader implementation of prevention strategies tied to vaccination, elevated awareness among populations at higher risk for the disease, and a substantial increase in investment allocated to research concerning rare liver diseases. Significant trends anticipated during this forecast period encompass a growing emphasis on the early identification of co-infections, the escalating adoption of sophisticated serologic testing methods, a greater demand for treatment protocols tailored to specific patient needs, the expansion of disease management programs within hospital settings, and a reinforced focus on raising public awareness about the condition.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21202&type=smp

Hepatitis D Market Industry Drivers: What Is Driving Revenue Growth?

The expanding incidence of hepatitis B is anticipated to be a significant catalyst for the upward trajectory of the hepatitis D market. Hepatitis B, a viral ailment impacting the liver, manifests with symptoms like jaundice, weariness, and discomfort in the abdominal region, and its untreated progression can result in chronic liver conditions or hepatic malignancy. Several elements contribute to the escalating numbers of hepatitis B infections, including unshielded intimate encounters, the communal use of injection paraphernalia, transmission from mother to infant during birth, and inadequate immunization rates in specific geographic areas. Essential for its own multiplication, hepatitis D is dependent on the hepatitis B virus, utilizing the latter’s surface antigen to infiltrate liver cells, thus rendering the concurrent infection by both viruses a crucial determinant in the advancement of liver ailments. Illustratively, as of April 2025, data from the Department of Health and Human Services, a governmental entity within the United States, revealed that 17,650 new instances of chronic hepatitis B were documented throughout 2023, accompanied by 1,769 fatalities linked to hepatitis B during the same year. Consequently, the growing ubiquity of hepatitis B infections is directly fueling the expansion observed in the hepatitis D market.

Hepatitis D Market Segment Outlook: Which Categories Are Expanding The Fastest?

The hepatitis d market covered in this report is segmented –

1) By Type: Acute, Chronic

2) By Diagnosis: Blood Tests, Elastography, Liver Biopsy, Serologic Testing, Other Diagnosis

3) By Distribution Channel: Hospital pharmacies, Retail pharmacies

4) By End-Users: Clinic, Hospital, Other End Users

Subsegments:

1) By Acute: Self-limiting Acute Hepatitis D, Severe Acute Hepatitis D

2) By Chronic: Compensated Chronic Hepatitis D, Decompensated Chronic Hepatitis D

#Hepatitis D Market Growth Trends: What Is Influencing The Future Outlook?

Key players within the hepatitis D market are prioritizing the creation of novel approaches, including RNA-targeted antiviral therapies, to enhance treatment effectiveness and fulfill the existing gaps in managing chronic hepatitis D. This therapeutic strategy involves directly interfering with a virus’s RNA to impede its reproduction, disrupt the synthesis of viral components, or deactivate viral genetic material, leading to a decrease in virus quantity and better disease control. Illustrating this progress, Vir Biotechnology Inc., a biotechnology firm situated in the United States, secured significant regulatory endorsements in December 2024: the U.S. Food and Drug Administration (FDA) granted it Breakthrough Therapy status, and the European Medicines Agency (EMA) awarded it PRIME (Priority Medicines) designation for its dual-action treatment comprising tobevibart and elebsiran aimed at chronic hepatitis delta (CHD).

Hepatitis D Market Key Companies And Competitive Benchmarking

Major companies operating in the hepatitis d market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Viatris Inc., VBI Vaccines Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dynavax Technologies Corporation, Echosens S.A., Arbutus Biopharma Corporation, PROBIOMED SA de CV, Assembly Biosciences Inc., Replicor Inc., Eiger BioPharmaceuticals Inc., Bluejay Therapeutics Inc., Janssen Pharmaceuticals Inc., Transgene SA, Vir Biotechnology Inc., Biorex Diagnostics Ltd.

Access The Complete Hepatitis D Market Report:

https://www.thebusinessresearchcompany.com/report/hepatitis-d-global-market-report

Hepatitis D Market Leading Geography: Which Region Generates The Most Revenue?

North Americawas the largest region in the hepatitis D market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis d market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model